| Website | promedior.com |
| Category | BioTech |
| Phone | 610.560.1435 |
| info@promedior.com | |
| Employees | |
| Founded | 2006 |
| Description | Biopharmaceutical Company |
| TOTAL | $50.5M |
| FUNDING TOTAL | $50.5M |
| Series A, 5/06 Polaris Partners HealthCare Ventures Trellis Bioscience Easton Capital Morgenthaler Ventures | $14M |
| Series C, 3/10 Forbion Capital Partners | $12M |
| Series D, 3/12 Fibrotic Ventures Morgenthaler Ventures HealthCare Ventures Polaris Partners Forbion Capital Partners Easton Capital | $21.5M |
| Series D, 10/12 Shire | $3M |
Promedior is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and fibrotic diseases
Promedior has developed a novel drug discovery platform to regulate the monocyte-derived cell populations that play key roles in fibrotic, inflammatory and autoimmune diseases. By specifically targeting these cells at the site of injury, Promedior is able to treat the source of aberrant immune system responses, promote tissue healing and resolution, and greatly reduce the risk of systemic side effects inherent in current therapeutic approaches.
Promedior is developing drugs to address the most severe and difficult-to-treat fibrotic and inflammatory conditions of the eye, lung and kidney such as glaucoma, age-related macular degeneration, diabetic retinopathy and dry eye disease; pulmonary fibrosis, scleroderma and COPD; and acute and chronic nephropathy.
